Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer.
Humans
Adult
Middle Aged
Aged
Aged, 80 and over
Carboplatin
/ therapeutic use
Paclitaxel
Cisplatin
/ therapeutic use
Squamous Cell Carcinoma of Head and Neck
/ drug therapy
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Neoplasm Recurrence, Local
/ drug therapy
Head and Neck Neoplasms
/ drug therapy
Chemoradiotherapy
/ adverse effects
cisplatin ineligible
concurrent carboplatin and paclitaxel
locally advanced head and neck cancer
older age and comorbidities
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
27
05
2023
received:
27
02
2023
accepted:
29
06
2023
medline:
11
8
2023
pubmed:
13
7
2023
entrez:
13
7
2023
Statut:
ppublish
Résumé
We report the outcomes of cisplatin-ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel. We included consecutive HNSCC patients treated from 2013 to 2021 that received definitive chemoradiation with carboplatin and paclitaxel. Locoregional recurrences (LRR) and distant metastases (DM) were estimated using cumulative incidence functions. Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier methods. Sixty-five patients were identified with median age of 71 years (range 44-85). Median radiation dose was 70 Gy and the median doses of carboplatin and paclitaxel were AUC 1 and 40 mg/m Chemoradiation with carboplatin and paclitaxel is an excellent option for cisplatin-ineligible HNSCC patients.
Sections du résumé
BACKGROUND
We report the outcomes of cisplatin-ineligible HNSCC patients treated with definitive chemoradiation and concurrent carboplatin and paclitaxel.
MATERIALS AND METHODS
We included consecutive HNSCC patients treated from 2013 to 2021 that received definitive chemoradiation with carboplatin and paclitaxel. Locoregional recurrences (LRR) and distant metastases (DM) were estimated using cumulative incidence functions. Progression free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier methods.
RESULTS
Sixty-five patients were identified with median age of 71 years (range 44-85). Median radiation dose was 70 Gy and the median doses of carboplatin and paclitaxel were AUC 1 and 40 mg/m
CONCLUSIONS
Chemoradiation with carboplatin and paclitaxel is an excellent option for cisplatin-ineligible HNSCC patients.
Substances chimiques
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2207-2216Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Pignon JP, Maître A l, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17 346 patients. Radiother Oncol. 2009;92(1):4-14. doi:10.1016/J.RADONC.2009.04.014
Lacas B, Carmel A, Landais C, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19 805 patients, on behalf of MACH-NC group. Radiother Oncol. 2021;156:281-293. doi:10.1016/J.RADONC.2021.01.013
Zakeri K, Rotolo F, Lacas B, et al. Predictive classifier for intensive treatment of head and neck cancer. Cancer. 2020;126(24):5263-5273. doi:10.1002/CNCR.33212
Jhawar SR, Bonomi M, Harari PM. Treating advanced head and neck cancer when cisplatin is not an option. J Clin Oncol. 2021;39(1):7-12. doi:10.1200/JCO.20.02720
Caudell JJ, Gillison ML, Maghami E, et al. NCCN Guidelines® insights: head and neck cancers, version 1.2022. J Natl Compr Cancer Netw. 2022;20(3):225-234. doi:10.6004/JNCCN.2022.0016
Patil VM, Noronha V, Menon N, et al. Results of phase III randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation. J Clin Oncol. 2023;41(13):2350-2361. doi:10.1200/JCO.22.00980
Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187-199. doi:10.1016/S1470-2045(14)71207-0
van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-2084. doi:10.1056/NEJMOA1112088/SUPPL_FILE/NEJMOA1112088_DISCLOSURES.PDF
Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology. 2014;87(2):125-132. doi:10.1159/000361051
Tinker AV, Bhagat K, Swenerton KD, Hoskins PJ. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol Oncol. 2005;98(1):54-58. doi:10.1016/J.YGYNO.2005.03.037
Agarwala SS, Cano E, Heron DE, et al. Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Ann Oncol. 2007;18(7):1224-1229. doi:10.1093/ANNONC/MDM088
Suntharalingam M, Haas ML, Conley BA, et al. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2000;47(1):49-56. doi:10.1016/S0360-3016(00)00408-9
Chougule PB, Akhtar MS, Rathore R, et al. Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck cancer: long-term follow-up of a Brown University Oncology Group Phase II Study (HN-53). Head Neck. 2008;30(3):289-296. doi:10.1002/HED.20700
Maring S, Elsayad K, Stenner M, et al. Efficacy of carboplatin/paclitaxel-based radiochemotherapy in locally advanced squamous cell carcinoma of head and neck. Oncol Res Treat. 2018;41(12):736-743. doi:10.1159/000494031
Karivedu V, Bonomi M, Issa M, et al. Treatment outcomes of head and neck cancer patients in the elderly receiving different chemoradiation combinations: a single-center experience. Oncol Res Treat. 2021;44(10):521-529. doi:10.1159/000518548
Roskies M, Kay-Rivest E, Mascarella MA, Sultanem K, Mlynarek A, Hier M. Survival outcomes in patients with oropharyngeal cancer treated with carboplatin/paclitaxel and concurrent radiotherapy. J Otolaryngol Head Neck Surg. 2016;45(1):1-6. doi:10.1186/S40463-016-0163-1
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21-28. doi:10.1016/S1470-2045(09)70311-0
Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2019;393(10166):51-60. doi:10.1016/S0140-6736(18)32752-1/ATTACHMENT/FBACF3BD-CD7C-4549-B17A-2DC69AC7EC5B/MMC1.PDF
Rischin D, King M, Kenny L, et al. Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01)-a trans-Tasman radiation oncology group study. Int J Radiat Oncol Biol Phys. 2021;111(4):876-886. doi:10.1016/J.IJROBP.2021.04.015
Gebre-Medhin M, Brun E, Engström P, et al. ARTSCAN III: a randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer. J Clin Oncol. 2021;39(1):38-47. doi:10.1200/JCO.20.02072
Riaz N, Sherman E, Koutcher L, et al. Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2016;39(1):27-31. doi:10.1097/COC.0000000000000006
Koutcher L, Sherman E, Fury M, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):915-922. doi:10.1016/J.IJROBP.2010.07.008
Tsai CJ, McBride SM, Riaz N, et al. Evaluation of substantial reduction in elective radiotherapy dose and field in patients with human papillomavirus-associated oropharyngeal carcinoma treated with definitive chemoradiotherapy. JAMA Oncol. 2022;8(3):364-372. doi:10.1001/JAMAONCOL.2021.6416
Mell LK, Torres-Saavedra P, Wong S, et al. Radiotherapy with durvalumab vs. cetuximab in patients with locoregionally advanced head and neck cancer and a contraindication to cisplatin: phase II results of NRG-HN004. Int J Radiat Oncol Biol Phys. 2022;114(5):1058. doi:10.1016/J.IJROBP.2022.09.003
Zumsteg ZS, Lok BH, Ho AS, et al. The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era. Cancer. 2017;123(8):1345-1353. doi:10.1002/CNCR.30495
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the. Head Neck. 2006;354(6):567-578. doi:10.1056/NEJMOA053422
Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40-50. doi:10.1016/S0140-6736(18)32779-X
Aisner J, Sinibaldi V, Eisenberger M. Carboplatin in the treatment of squamous cell head and neck cancers. Semin Oncol. 1992;19(1 Suppl 2):60-65. Accessed May 19, 2023. https://europepmc.org/article/med/1411628
Eisenberger M, Hornedo J, Silva H, Donehower R, Spaulding M, Van Echo D. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1986;4(10):1506-1509. doi:10.1200/JCO.1986.4.10.1506
Rowinsky EK, Donehower RC. Paclitaxel (Taxol). New Engl J Med. 1995;135(12):393-396. doi:10.1056/NEJM199504133321507
Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer. 2006;42(1):24-30. doi:10.1016/J.EJCA.2005.06.030
Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol. 2010;28(16):2732-2738. doi:10.1200/JCO.2009.24.6199
Xiang M, Holsinger FC, Colevas AD, Chen MM, Le QT, Beadle BM. Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: a surveillance, epidemiology, and end results-Medicare analysis. Cancer. 2018;124(23):4486-4494. doi:10.1002/CNCR.31708
Sun L, Candelieri-Surette D, Anglin-Foote T, et al. Cetuximab-based vs carboplatin-based chemoradiotherapy for patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2022;22:1022. doi:10.1001/JAMAOTO.2022.2791
Beckham TH, Barney C, Healy E, et al. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer. Int J Cancer. 2020;147(1):107-115. doi:10.1002/IJC.32736
Behera M, Owonikoko TK, Kim S, et al. Concurrent therapy with taxane versus non-taxane containing regimens in locally advanced squamous cell carcinomas of the head and neck (SCCHN): a systematic review. Oral Oncol. 2014;50(9):888-894. doi:10.1016/J.ORALONCOLOGY.2014.06.014
Cmelak AJ, Murphy BA, Burkey B, Douglas S, Shyr Y, Netterville J. Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial. Head Neck. 2007;29(4):315-324. doi:10.1002/HED.20522
Wanebo HJ, Lee J, Burtness BA, et al. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Ann Oncol. 2014;25(10):2036-2041. doi:10.1093/ANNONC/MDU248
Vlacich G, Diaz R, Thorpe SW, et al. Intensity-modulated radiation therapy with concurrent carboplatin and paclitaxel for locally advanced head and neck cancer: toxicities and efficacy. Oncologist. 2012;17(5):673-681. doi:10.1634/THEONCOLOGIST.2011-0396
Kang JJ, Yu Y, Chen L, et al. Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer. CA Cancer J Clin. 2022;73(2):164-197. doi:10.3322/CAAC.21758
Zakeri K, Dunn L, Lee N. HPV-associated oropharyngeal cancer de-escalation strategies and trials: past failures and future promise. J Surg Oncol. 2021;124(6):962-966. doi:10.1002/JSO.26696